Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?

Aug 08 2022

• By Alaric DeArment

Amgen presented data for Lumakras at the World Conference on Lung Cancer • Source: Shutterstock

Related Content

Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch

May 29 2021

Mirati Generates Cautious Optimism With KRAS/PD-1 Combo Data

Nov 09 2021

Amgen’s $3.7bn ChemoCentryx Buy May Help Offset Growing Pains

Aug 05 2022

Combinations Key For Amgen’s Lumakras, But PD-1/L1 Data Held Until August

Jul 13 2022

Related Companies

Amgen, Inc.

Merck & Co., Inc.

Mirati Therapeutics, Inc.

Roche Holding AG

Revolution Medicines, Inc.

Additional Topics

ImmunoOncology Business Strategies Research & Development Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window